News | February 17, 2024
Internal restructuring of foreign subsidiaries at Bliss GVS Pharma
The restructuring aims to create synergies across the business and strengthen capital structure
The restructuring aims to create synergies across the business and strengthen capital structure
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
The registered capital of the newly founded company is € 50 million
An accomplished R&D leader and champion of the application of AI to drug discovery
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Subscribe To Our Newsletter & Stay Updated
